Literature DB >> 1425421

Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone.

Y Ohsaki1, S Takahashi, T Scarcez, A Demulder, T Nishihara, R Williams, G D Roodman.   

Abstract

Interleukin-6 (IL-6) is a multifunctional cytokine whose role in osteoclastic bone resorption has not been clearly defined. Therefore, we have used giant cells, which express many features of osteoclasts, from giant cell tumors of bone as a model to examine the role that IL-6 may play in human osteoclastic bone resorption. We found that conditioned medium from 24-h cultures of highly purified giant cells (10(6)/ml) contained large amounts of IL-6 (37.9 +/- 8.8 ng/ml), similar to the amount of IL-6 produced by tumor stromal cells (29.8 +/- 11.5 ng/ml). Giant cells and stromal cells from giant cell tumors expressed IL-6 mRNA, as indicated by polymerase chain reaction analysis and in situ hybridization studies, and immunohistochemical techniques demonstrated that the giant cells expressed IL-6 receptors. The addition of a neutralizing antibody to IL-6 significantly decreased the area of dentine resorbed by purified giant cells in a dose-dependent manner, and the addition of IL-6 to cultures of purified giant cells pretreated with anti-IL-6 restored the resorbing capacity of the giant cells. These data suggest that IL-6 may act as both an autocrine and a paracrine factor for human osteoclasts and play an important role in the bone-resorbing capacity of these cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425421     DOI: 10.1210/endo.131.5.1425421

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  25 in total

1.  Differential gene expression in stromal cells of human giant cell tumor of bone.

Authors:  M Wuelling; G Delling; E Kaiser
Journal:  Virchows Arch       Date:  2004-09-23       Impact factor: 4.064

Review 2.  Giant cell tumour of bone: morphological, biological and histogenetical aspects.

Authors:  Mathias Werner
Journal:  Int Orthop       Date:  2006-09-30       Impact factor: 3.075

3.  Collagenase expression and activity in the stromal cells from giant cell tumour of bone.

Authors:  Robert W Cowan; Isabella W Y Mak; Nigel Colterjohn; Gurmit Singh; Michelle Ghert
Journal:  Bone       Date:  2009-02-12       Impact factor: 4.398

4.  Intratibial injection of patient-derived tumor cells from giant cell tumor of bone elicits osteolytic reaction in nude mouse.

Authors:  Leqin Xu; Zhipeng Wu; Zhenhua Zhou; Xinghai Yang; Jianru Xiao
Journal:  Oncol Lett       Date:  2018-07-16       Impact factor: 2.967

Review 5.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

6.  The biochemical origin of pain--proposing a new law of pain: the origin of all pain is inflammation and the inflammatory response. Part 1 of 3--a unifying law of pain.

Authors:  Sota Omoigui
Journal:  Med Hypotheses       Date:  2007-01-19       Impact factor: 1.538

7.  Annexin II increases osteoclast formation by stimulating the proliferation of osteoclast precursors in human marrow cultures.

Authors:  C Menaa; R D Devlin; S V Reddy; Y Gazitt; S J Choi; G D Roodman
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

Review 8.  Role of cytokines in the regulation of bone resorption.

Authors:  G D Roodman
Journal:  Calcif Tissue Int       Date:  1993       Impact factor: 4.333

9.  Catecholamines modulate growth and differentiation of human preosteoclastic cells.

Authors:  U Frediani; L Becherini; L Lasagni; A Tanini; M L Brandi
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

10.  Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer.

Authors:  Y Okugawa; C Miki; Y Toiyama; H Yasuda; T Yokoe; S Saigusa; J Hiro; K Tanaka; Y Inoue; M Kusunoki
Journal:  Br J Cancer       Date:  2010-09-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.